

**SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST**

**EXECUTIVE SUMMARY**

**REPORT TO THE BOARD OF DIRECTORS MEETING**

**HELD ON 26<sup>th</sup> JANUARY 2021**

<b>Subject</b>	2020/21 to 2024/25 Capital Programme
<b>Supporting TEG Member</b>	Neil Priestley
<b>Author</b>	Neil Priestley
<b>Status<sup>1</sup></b>	A/N

**PURPOSE OF THE REPORT**

To provide an update on the 2020/21 Capital Programme and the 5 Year Capital Plan.

**KEY POINTS**

1. The Capital Programme remains manageable for 2020/21 and 2021/22 but the 5 Year Plan potentially moves into a significant over committed position from 2023/24 onwards.
2. This over-committed position is likely to be exacerbated as new schemes and priorities emerge over the medium term such that funding solutions will be required.
3. In addition, major schemes such as the WPCCC Transformation and a new EPR will require specific funding solutions and external support if they are to progress.
4. Given the COVID-19 impact and a range of additional national funding allocations, a significant underspend against available resources is likely in 2020/21. However, current plans still assume a major investment of £46.5m.
5. Capital planning/prioritisation and scheme “value engineering” continue to be crucial in securing maximum value for money from constrained resources.
6. System Operational Capital Envelopes are adding a new level of complexity to capital planning.

**IMPLICATIONS<sup>2</sup>**

<b>AIM OF THE STHFT CORPORATE STRATEGY 2017-2020</b>		<b>TICK AS APPROPRIATE</b>
1	Deliver the Best Clinical Outcomes	
2	Provide Patient Centred Services	
3	Employ Caring and Cared for Staff	
4	Spend Public Money Wisely	✓
5	Deliver Excellent Research, Education & Innovation	

**RECOMMENDATIONS**

As per Section 7 of the report.

**APPROVAL PROCESS**

<b>Meeting</b>	<b>Date</b>	<b>Approved Y/N</b>

<sup>1</sup> Status: A = Approval  
D = Debate  
N = Note

<sup>2</sup> Against the five aims of the STHFT Corporate Strategy 2017-2020

# **SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST**

## **BOARD OF DIRECTORS 26<sup>th</sup> JANUARY 2021**

### **2020/21 TO 2024/25 CAPITAL PROGRAMME – QUARTER 3 UPDATE**

#### **1. INTRODUCTION**

- 1.1 This report continues the process of monitoring progress on the Trust's Capital Programme for the period 2020/21 to 2024/25. It considers the position at the end of January 2021 and outlines the major changes since approval of the 5 Year Capital Plan and 2020/21 Capital Programme by the Trust Board in October 2020.
- 1.2 Given financial uncertainties, the capital plans do not assume future I&E surpluses to support the Capital Programme. However, the cash gains from the surpluses in previous financial years are incorporated into the programme. As in previous reports, the 5 Year Plan includes a £6m pa assumption of need for significant schemes in future years. It is worth noting, however, that the revised arrangements for controlling provider capital expenditure through System Operational Capital Envelopes means that there is no guarantee of being able to invest previous surpluses.
- 1.3 The current cumulative plan over-commitment over the period, at £17.9m, remains broadly in line with the position at October. The cumulative position does not become a major concern until year four of the plan, although there are a number of potential high value schemes which may place additional pressure on the capital programme before this time.
- 1.4 Appendix A includes a list of these “probable” and “possible” schemes which are not yet included on the Capital Programme/Plan but require consideration. Recovery from the Covid pandemic may also drive further need. There are also a number of potential major schemes which require separate funding arrangements, i.e. WPC Transformation, a new EPR and SYB Pathology Network. Careful management will therefore be required to achieve an overall balanced position, necessitating difficult decisions around funding availability, scheme prioritisation and investment timings.
- 1.5 The current capital expenditure plan for 2020/21 stands at £46.5m. This remains a very challenging programme reflecting many complex operational and logistical issues, even before the additional complexities of COVID-19 implications. Some major schemes which commenced during 2019/20 have completed during the first half of the year but there is a high risk of slippage on new schemes given the new challenges in planning and scheme delivery, and the diversion of attention onto COVID-19 and other nationally funded priorities.

#### **2. OVERVIEW OF THE CAPITAL PROGRAMME AND PLAN**

- 2.1 The capital programme for 2020/21 – 2024/25 as Appendix B shows the following position:-

	<b>2020/21 £m</b>	<b>2021/22 £m</b>	<b>2022/23 £m</b>	<b>2023/24 £m</b>	<b>2024/25 £m</b>
Funding Available	60.2	35.1	25.6	21.4	21.5
Expenditure Plan	(46.5)	(47.0)	(21.4)	(21.4)	(21.4)
<b>Under/(Over) Commitment</b>	<b>13.7</b>	<b>(11.9)</b>	<b>4.2</b>	<b>0.0</b>	<b>0.1</b>
<b>Cumulative Under/(Over) Commitment</b>		<b>1.8</b>	<b>6.0</b>	<b>6.0</b>	<b>6.1</b>

- 2.2 As previously, the Capital Programme reflects a manageable position for this year and next. However, the five year Capital Plan still has a £17.9m over-commitment. Appendix A demonstrates the profile of this over-commitment but also shows the level of “probable” schemes which far exceed the annual £6m allowance within the plan. It is therefore clear that addressing the funding gap will be a challenge.
- 2.3 Following the issue of ICS 2020/21 “Operational Capital” envelopes in May, the Trust was asked to reduce its planned capital expenditure (excluding donations) for the year to an “envelope” of £38.5m (including £4.6m of PDC funding). The Trust agreed given the impact of likely slippage within the programme, alongside management of COVID-19 requirements and disruption to contractors and supply chains.
- 2.4 However, further national capital funding (in addition to the initial “envelope”) has also been allocated to the Trust in-year, i.e. £12.8m for Critical Infrastructure Risks and an estimated £3.2m for COVID-19. £1.1m of the Capital COVID-19 funds are still awaiting national confirmation. These additional schemes have added to the complexity and challenges of delivering the programme.
- 2.5 The combined impact of normal slippage, Covid disruption and the additional funding mean that the Trust is currently reporting an underspend against available resources in 2020/21 of £13.7m. This equates to an undershoot against the system “envelope” of £8.3m. Expected further slippage (see 2.7 below) will almost certainly cause these figures to increase by £3m or so.
- 2.6 The Capital Programme includes a number of high priority schemes which have recently received approval. These include:
- ◆ CCDH COVID restart refurbishment - £1.9m
  - ◆ Refurbishment Central Clinic/Centralised Pre-Operative Assessment unit - £0.6m
  - ◆ Liquid Chromatography Mass Spectrometry machines x 2 - £0.4m
  - ◆ IT Data Centres (£0.2m) & Data Centre Switches (£0.5m) - £0.7m
  - ◆ Replacement Flexpod £1.4m
- 2.7 Appendix C provides an update on the current quantified risks or cost adjustments anticipated on existing schemes. The summary also shows estimated further net slippage (£3.3m), which will need close management alongside the ICS.

### **3. ADDITIONAL FUNDING**

- 3.1 The assumed funding in the 2020/21 Capital Programme consists of:
- ◆ Internally generated resourced of £20.6m from forecast depreciation (net of around £2.5m of loan repayments).
  - ◆ Application of half of the 2018/19 I&E surplus/STF Funding - £13.7m
  - ◆ PDC: Confirmed receipt for HASU £4.7m and Critical Infrastructure Risks £12.8m, and assumed receipt for COVID-19 capital costs £3.2m.
  - ◆ Lease funding for laboratory equipment - £0.4m
  - ◆ £3.6m from reinvestment of the underspend from 2018/19.
  - ◆ £1.2m from “donations” and forecast VAT recovery.
- 3.2 There has been an increase in cumulative funding available from October of £0.1m, mainly from the receipt of grant funding to progress decarbonisation proposals. Further VAT recovery is expected to be confirmed by the end of January following finalisation of the contracted out services review for the 2019/20 financial year.

3.3 The cash gain from the 2019/20 surplus has been profiled into 2022/23.

#### **4. CHANGES TO APPROVED PROGRAMME**

4.1 There have been many changes to approved expenditure since the October update due to new scheme approvals, in-year re-profiling, allocation of specific schemes from ring-fenced envelopes and cost updates on existing schemes.

4.2 In headline terms the 2020/21 programmed expenditure at October of £51.5m has decreased by £5.0m to £46.5m, mainly due to £1.0m investment in CCDH to enable the restart of dental services in a COVID secure environment, £0.1m grant funded expenditure for development of decarbonisation schemes, £0.1m new PDC/donations and £6.2m net confirmed slippage to 2021/22.

4.3 Slippage from 2020/21 to 2021/22 reflects many schemes, with the most significant elements relating to Infrastructure schemes given the focus on national Critical Infrastructure Risk schemes (£4.7m), slippage on minor medical equipment investments (£1.0m) and planning delays associated with the Major Medical Equipment envelope (£0.5m).

4.5 Major new scheme approvals have been highlighted at paragraph 2.6 above.

#### **5. FURTHER RISKS AND CONTINGENCIES**

5.1 Appendix C identifies the quantified major risks to the capital position.

5.2 Other risks to delivering the 2020/21 Capital Programme and 5 Year plan are:

- ◆ The current £17.9m over commitment on the 5 Year Plan which may be increased by further unavoidable schemes (see Appendix A) – **High Risk**. Mitigating actions include:
  - Attracting PDC/ICS funding, particularly in relation to WPH bunkers.
  - Loans/Leases.
  - Use of working capital balances (if not restricted by new national considerations or used to finance I&E deficits)
  - Additional charitable donations/contributions
  - Further reducing ring-fenced budgets/restrictions or scheme approvals
- ◆ Increased costs for existing schemes – **Medium/High Risk**. Mitigating actions include robust case scrutiny, tight management of scheme specifications and firm cost control as schemes progress.
- ◆ Risk of further major slippage on 2020/21 schemes, due to operational and logistical barriers inherent in managing a major programme of over £45m whilst maintaining COVID-19 social distancing and safely restarting patient services – **High Risk**. Mitigating actions include tight planning and forecasting, prompt actions in developing and finalising schemes and identification/approval of mitigating actions including options to advance schemes.
- ◆ Diversion of Trust resources (Estates, IT, Clinical Engineering, Planning, Procurement and Finance) onto management of COVID-19 priorities and nationally driven initiatives thereby compounding the slippage risk – **Medium Risk**. Mitigating actions will include ensuring BAU can be maintained as far as possible and highlighting the importance of delivering the capital plans.

- ◆ Poor prioritisation of potential schemes – **Low Risk**. Mitigating actions include good strategic, business and capital planning with a clear understanding of the environment and close working with Directorates.
  - ◆ Risks relating to the progression of the WPC Transformation, new EPR and SYB Pathology Network schemes including funding, scheme progression/delivery, financial planning, operational change and transition – **Medium Risk**. Mitigating actions will include strong governance arrangements, developing knowledge and skills within the organisation, excellent planning and good communication.
  - ◆ Risks associated with the adequacy of the System Operational Capital Envelope to enable the Trust to utilise resources from past I&E surpluses and/or enable a sufficient level of capital investment each year – **High Risk**. Mitigating actions include working closely with system colleagues to allocate the envelope, supporting proposals for an increase to the envelope, securing alternative funding sources and ensuring that the Trust’s capital investment plans are robust.
- 5.3 Prioritisation against the ring-fenced budgets for 2020/21 is complete although an additional review of the Minor Medical Equipment envelope is proposed to determine if any further action is possible.
- 5.4 Business planning/capital prioritisation; strong links to external funding sources; grasp of logistical and practical scheme co-ordination; and “value engineering” will be critical in order to secure maximum value for money from potentially constrained capital funding/approval to spend. Revenue affordability will also remain a key issue.

## 6. **BUSINESS CASES**

- 6.1 The Capital Programme at Appendix B formally identifies the status of all current capital schemes.
- 6.2 Fees have been allocated for work in developing Business Cases for the following schemes:
- ◆ 7<sup>th</sup> MRI Scanner
  - ◆ NGH Washer Disinfector Replacement
  - ◆ Firth 7/CCU
  - ◆ Gastroenterology Facilities
  - ◆ NGH Radiology Outpatients
  - ◆ JHW Ward Refurbishment
  - ◆ Chesterman Theatres
  - ◆ NGH CHP
  - ◆ RHH B Road Water Flooding
  - ◆ JHW Theatres
- 6.3 Since the Capital Programme and 5 Year Plan were approved at the Trust Board meeting in October, the following schemes have formally commenced:
- ◆ Wheata Place Community Dental
  - ◆ Endocrine Investigation Unit (RHH)
  - ◆ RHH A Floor Theatres Phase 5
  - ◆ A range of Critical Infrastructure Risk schemes
  - ◆ CCDH COVID Restart
  - ◆ Central Clinic Refurbishment/Pre-Operative Assessment
  - ◆ NGH Firth Operating Theatres 17 and 18

6.4 A number of schemes have also been completed since the Capital Programme and Plan were approved in October, with the most notable being:

- ◆ 8<sup>th</sup> Linear Accelerator
- ◆ Manor Clinic Community Dental
- ◆ Clinical Immunology & Allergy Phase 1
- ◆ RHH A Floor Theatres Phase 4

## 7. **RECOMMENDATIONS**

The Board of Directors is asked to

- 7.1 Approve the latest 2020/21 Capital Programme and note the significant over-commitment on the 2023/24 to 2024/25 position, which will need to be addressed via an appropriate combination of the funding solutions proposed.
- 7.2 Note the list of “probable” and “possible” schemes on the five year plan at Appendix A which, along with other likely schemes which will emerge over the five year period, will require further consideration and careful prioritisation.
- 7.3 Note the risks outlined in Section 5 above, and the need to continue to generate additional resources for future years, ensure approval to utilise such resources and identify any opportunities to secure additional capital funding.
- 7.4 Note the 2020/21 capital expenditure position and the close attention required to minimise the year end outturn underspend.
- 7.5 Note the importance of capital planning/prioritisation and “value engineering” in securing maximum benefits from limited capital and revenue funding.

Neil Priestley  
Director of Finance  
January 2021

## 2020/21 - 2024/25 CAPITAL PLAN

		2020/21	2021/22	2022/23	2023/24	2024/25	
		£	£	£	£	£	
2020/21 Capital Programme Position as at 19/1/21		13,754,000	-11,871,000	4,157,000	12,000	79,000	
Other PDC/Income Sources		?	?	?	?	?	
Reduction in Ringfence envelopes							
Future Probable/Possible Schemes	-24,000,000	0	-6,000,000	-6,000,000	-6,000,000	-6,000,000	
<b>Projected Annual Capital Programme Position as at 19/1/21</b>		<b>13,754,000</b>	<b>-17,871,000</b>	<b>-1,843,000</b>	<b>-5,988,000</b>	<b>-5,921,000</b>	
<b>Cumulative Projected Capital Programme Position as at 19/1/21</b>		<b>13,754,000</b>	<b>-4,117,000</b>	<b>-5,960,000</b>	<b>-11,948,000</b>	<b>-17,869,000</b>	

	Assumed Funding		2020/21	2021/22	2022/23	2023/24	2024/25	
			£	£	£	£	£	
<b>Other "Probable" Schemes</b>								
Add'l Linear Accelerator Bunkers x2	Internal	B	-100,000	-2,000,000	-4,600,000			Assumed need for x2 bunkers. Pre-planning application submitted.
Cardiac Theatre Refurbishment	Internal	A			-1,000,000	-2,000,000	-1,500,000	Scheme being developed to follow Main NGH Theatres scheme. Possible link to Hybrid Theatre.
Hybrid (Endovascular) Theatre	Internal	U		-300,000	-3,900,000			Options and financial feasibility under consideration.
JHW Theatres	Internal	A	-50,000	-1,000,000	-3,556,000			Cost reflects "mid" option presented to CIT 19/10/20. Approval to proceed to OBC
RHH Ward H1 Refurbishment	Internal	B		Inc in prog	-380,000			To be used for ISGM Dementia Ward. Needs HASU Ward L1 to complete.
Firth 7/CCU Refurbishment	Internal/Charitable	B			-1,300,000	-2,650,000		Indicative OBC costs less £300k enabling works approved. Potential use of Ward Refurb funding
Major Trauma Ward	Internal	B		-300,000	-1,500,000			Proposal to BPT
JHW Ward Refurbishment	Internal	B				-2,400,000	-3,505,000	£5.9m projected total cost - covers 2 Labour Wards, additional birthing pool and ventilation
Estates Generator Programme	Internal	U		-2,000,000	-4,000,000	-1,047,000		RHH Scheme £7047k as per OBC to CIT 1/6/20
Gastroenterology Facilities	Internal	U		-200,000	-3,200,000	-950,000	-500,000	Fees agreed CIT 25/11/19. Requires refurb of Ward H1 at RHH for decant space
Imaging Equipment Expansions	Internal	U		?	-2,000,000	-3,000,000		Assume some unavoidable equipment expansion over 5 year period e.g. 7th MRI and 3rd NGH CT
A&E Frontdoor/NGH Assessment Developments	Internal	U		-500,000	-2,500,000	-4,000,000	-3,500,000	Linked to reprovision of Fracture Clinic post 2022
Re-provision of Fracture Clinic	Internal	U		-500,000	-2,000,000			Would be enabled by Orthopaedics Reconfiguration scheme
Outpatient Facilities, RHH & NGH	Internal	U			-1,000,000	-2,640,000	-1,000,000	MSK approved. Wider Trust Strategy (post COVID-19) to be developed including Blood Disorders.
Dermatology Facilities	Internal	U				-2,000,000	-2,000,000	Concept paper for upgrade to facilities produced but being reconsidered.
NGH Radiology Outpatients	Internal	U		-500,000	-4,000,000			SOC to CIT 6/1/20
Orthopaedics Reconfiguration	Internal	U			-1,500,000	-500,000		Options to review
RHH B Road Water Proofing	Internal	U	?	-1,000,000	-1,000,000			Scoping work underway
Ward Refurbishment planning sum in Capital Programme				2,247,000	2,750,000	2,750,000	2,750,000	Available to offset v probable needs (£3597k) v Huntsman 5 & RHH Ward H1 within Programme
Theatre Refurbishment planning sum in Capital Programme				4,366,000	2,000,000	2,000,000	2,000,000	Available to offset v probable needs
<b>Total Approved and Probable Schemes</b>			<b>-50,960,000</b>	<b>-150,000</b>	<b>-1,687,000</b>	<b>-32,686,000</b>	<b>-16,437,000</b>	<b>-7,255,000</b>
<b>Possible Schemes</b>								
Critical Care Capacity	Internal	U				-5,000,000		Requirement unclear but potential requirement in 5 year period
Community Facilities - Intermediate Care Facility	Internal	U					-12,000,000	No further progress
Private Patient Facilities	External	U					-1,000,000	Scheme(s) dependent upon clinical opportunity/facility necessary.
Expansion/Upgrade of Bev Stokes	Internal	U			-3,000,000			Paused. Some refurbishment required. Likely smaller qualitative scheme
Palliative Care Unit Upgrade	Charitable	U				-2,500,000	-7,000,000	Consideration of options underway
Renal Ambulatory Unit	Internal	U					-500,000	Clinical model requires further consideration
Intra-Operative MRI Scanner (RHH A Floor)	Internal/Charitable	U			-100,000	-4,764,000		OBC to be refined. Potential for theatre area to be charitably funded
WPH MRI Simulator/MRI Linac	Internal	U		?	-1,500,000	?		Case of need to be submitted but not supported.
Ophthalmology Reconfiguration	Internal	U			-1,000,000	-950,000		Emerging £2m+ scheme
Longley Lane	Internal	U		-2,500,000				Potential uses include Car Parking, Phlebotomy Services, Community Diagnostic Hub, etc.
Intestinal Failure Service	Internal	U		?				Subject to tender exercise; outcome not yet known
Chesterfield Renal Satellite Unit	Internal	U			-1,200,000			Practical plan yet to be agreed
Other	?							New proposals likely
<b>Total Possible Schemes</b>			<b>-22,514,000</b>	<b>0</b>	<b>-2,500,000</b>	<b>-6,800,000</b>	<b>-13,214,000</b>	<b>-20,500,000</b>
<b>Schemes requiring separate funding source</b>								
WPCC Transformation	B			-500,000	-500,000	-7,000,000	-15,000,000	Transformation scheme at £60m being reconsidered. Further funding required in 25/26
EPR Reprocurement	B			-1,859,000	-23,092,000	-2,603,000		Based on best case, affordable model. Existing contract ends Sept 2022
SYB Pathology Reconfiguration	U			?	?	?		Requirement TBC
			<b>-35,554,000</b>	<b>0</b>	<b>-2,359,000</b>	<b>-23,592,000</b>	<b>-9,603,000</b>	<b>-15,000,000</b>

**SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST - 2020/21 - 2024/25 CAPITAL PROGRAMME**

**SUMMARY OF APPROVED SCHEMES AGAINST RESOURCES AVAILABLE**

**Appendix B**

CAPITAL PROGRAMME DETAILS	2020/21	2021/22	2022/23	2023/24	2024/25
<b>Total Funding Available</b>	<b>60,206,000</b>	<b>35,083,000</b>	<b>25,586,000</b>	<b>21,410,000</b>	<b>21,519,000</b>
Approved Scheme Details:					
Medical Equipment Modernisation	13,641,000	8,847,000	6,200,000	6,200,000	6,200,000
Information Technology	2,978,000	2,439,000	1,737,000	1,750,000	1,750,000
Service Development	10,604,000	9,586,000	3,550,000	3,550,000	3,550,000
Infrastructure	18,717,000	25,782,000	9,642,000	9,598,000	9,640,000
Leased Assets	449,000	0	0	0	0
Planned Rev-Cap Transfers	63,000	300,000	300,000	300,000	300,000
Funding for Unfunded Schemes	0	0	0	0	0
Directly Donated Equipment	0	0	0	0	0
<b>Approved Scheme Total</b>	<b>46,452,000</b>	<b>46,954,000</b>	<b>21,429,000</b>	<b>21,398,000</b>	<b>21,440,000</b>
<b>UNDER(OVER) COMMITMENT</b>	<b>13,754,000</b>	<b>-11,871,000</b>	<b>4,157,000</b>	<b>12,000</b>	<b>79,000</b>

APPROVED SCHEME DETAILS BY SITE	NGH					RHH					CCDH				
	2020/21	2021/22	2022/23	2023/24	2024/25	2020/21	2021/22	2022/23	2023/24	2024/25	2020/21	2021/22	2022/23	2023/24	2024/25
Medical Equipment Modernisation	3,504,000	273,000	0	0	0	2,453,000	81,000	0	0	0	288,000	0	0	0	0
Information Technology	160,000	686,000	0	0	0	551,000	0	0	0	0	0	0	0	0	0
Service Development	3,453,000	3,298,000	0	0	0	4,722,000	1,502,000	0	0	0	0	0	0	0	0
Infrastructure	8,221,000	1,629,000	692,000	648,000	690,000	8,397,000	6,206,000	0	0	0	1,001,000	900,000	0	0	0
Leased Assets	449,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Directly Donated Equipment															
<b>APPROVED SCHEME TOTAL</b>	<b>15,787,000</b>	<b>5,886,000</b>	<b>692,000</b>	<b>648,000</b>	<b>690,000</b>	<b>16,123,000</b>	<b>7,789,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1,289,000</b>	<b>900,000</b>	<b>0</b>	<b>0</b>	<b>0</b>

APPROVED SCHEME DETAILS BY SITE	JHW					WPH					CHS				
	2020/21	2021/22	2022/23	2023/24	2024/25	2020/21	2021/22	2022/23	2023/24	2024/25	2020/21	2021/22	2022/23	2023/24	2024/25
Medical Equipment Modernisation	209,000	120,000	0	0	0	2,092,000	0	0	0	0	197,000	0	0	0	0
Information Technology	0	0	0	0	0	5,000	0	0	0	0	0	0	0	0	0
Service Development	60,000	165,000	0	0	0	191,000	1,387,000	0	0	0	2,046,000	1,206,000	0	0	0
Infrastructure	10,000	0	0	0	0	17,000	0	0	0	0	928,000	25,000	0	0	0
Leased Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Planned Rev-Cap Transfers															
Funding for Unfunded Schemes															
Directly Donated Equipment															
<b>APPROVED SCHEME TOTAL</b>	<b>279,000</b>	<b>285,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2,305,000</b>	<b>1,387,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>3,171,000</b>	<b>1,231,000</b>	<b>0</b>	<b>0</b>	<b>0</b>

APPROVED SCHEME DETAILS BY SITE	STH UNALLOCATED				
	2020/21	2021/22	2022/23	2023/24	2024/25
Medical Equipment Modernisation	4,898,000	8,373,000	6,200,000	6,200,000	6,200,000
Information Technology	2,262,000	1,753,000	1,737,000	1,750,000	1,750,000
Service Development	132,000	2,028,000	3,550,000	3,550,000	3,550,000
Infrastructure	143,000	17,022,000	8,950,000	8,950,000	8,950,000
Leased Assets	0	0	0	0	0
Planned Rev-Cap Transfers	63,000	300,000	300,000	300,000	300,000
Funding for Unfunded Schemes	0	0	0	0	0
Directly Donated Equipment	0	0	0	0	0
<b>APPROVED SCHEME TOTAL</b>	<b>7,498,000</b>	<b>29,476,000</b>	<b>20,737,000</b>	<b>20,750,000</b>	<b>20,750,000</b>



## CAPITAL FUNDING AVAILABLE 2020/21 - 2024/25

	2020/21	2021/22	2022/23	2023/24	2024/25
	£	£	£	£	£
Projected Internally Generated Resources	35,367,000	35,367,000	35,367,000	35,367,000	35,367,000
Adjustment to Internally Generated Resources Forecast (July 10)	-6,994,000	-6,994,000	-6,994,000	-6,994,000	-6,994,000
Reduction in Depreciation from I&E surplus/indexation removal (based on LT Depn f/cast)	-1,717,000	-1,717,000	-1,717,000	-1,717,000	-1,717,000
Adjustment to Internally Generated Resources Forecast (Jan 14)	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000
Adjustment to Internally Generated Resources (Feb 15)	2,855,000	2,855,000	2,855,000	2,855,000	2,855,000
Adjustment to Internally Generated Resources (Jan 16)	-1,000,000	-1,000,000	-1,000,000	-1,000,000	-1,000,000
Adjustment to Internally Generated Resources (Jan 17)	-1,162,000	-1,162,000	-1,162,000	-1,162,000	-1,162,000
Adjustment to Internally Generated Resources (March 18 re MEA)	-6,200,000	-6,200,000	-6,200,000	-6,200,000	-6,200,000
Adjustment to Internally Generated Resources (March 19 re MEA)	-53,000	-53,000	-53,000	-53,000	-53,000
Adjustment to Internally Generated Resources (Feb 20 re 20/21 CCEs)	-53,000	-53,000	-53,000	-53,000	-53,000
Application of Internally Generated Resources to:					
- Hadfield Loan Creditor (PF)	-468,000	-463,000	-658,000	-739,000	-769,000
- Critical Care Loan (FTFF)	-780,000	-780,000	-780,000	-780,000	-780,000
- Laboratory Medicine Loan (FTFF)	-666,000	-666,000	-666,000	-666,000	-666,000
- Gamma Knife Lease Creditor	-511,000	-131,000	-131,000	0	0
- Gamma Knife Lease Source Upgrade Creditor	113,000	-285,000	24,000	0	0
- Wi-Fi Network	-130,000	-133,000	-136,000	-139,000	0
- High Resolution Mass Spectrometer (estimate pending lease tender)	-47,000	-62,000	-62,000	-62,000	-62,000
- Bard Ultrasound	-7,000	-7,000	-1,000	0	0
<b>Subtotal Internally Generated Resources</b>	<b>20,600,000</b>	<b>20,569,000</b>	<b>20,686,000</b>	<b>20,710,000</b>	<b>20,819,000</b>
Hyper Acute Stroke Unit	4,653,000				
COVID-19	2,176,000				
Urgent & Emergency Care	0				
Critical Risk Infrastructure	12,778,000				
Adapt & Adopt - Radiology Home Working Workstations	405,000				
Adapt & Adopt - Endoscopy Recovery	305,000				
Critical Care	316,000				
Pathology - ICE Interface to SCH	31,000				
<b>Subtotal Strategic Capital Funding/PDC</b>	<b>20,664,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
High Resolution Mass Spectrometer Lease	449,000				
<b>Subtotal Lease Funding</b>	<b>449,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
2018/19 PSF applied to Capital Programme	13,692,000	13,692,000			
2019/20 Year End Utilisation of/(Improvement to) Working Capital	3,612,000				
2019/20 I&E cash gain applied to Capital Programme			4,200,000		
<b>Subtotal Internal Use of Working Capital balances</b>	<b>17,304,000</b>	<b>13,692,000</b>	<b>4,200,000</b>	<b>0</b>	<b>0</b>
<b>Subtotal Internally Generated/Strategic Capital Funding/Lease Funding</b>	<b>59,017,000</b>	<b>34,261,000</b>	<b>24,886,000</b>	<b>20,710,000</b>	<b>20,819,000</b>
VAT Recovery	941,000	700,000	700,000	700,000	700,000
Replacement of 1.5T MRI - University of Sheffield	5,000				
NGH & RHH Junior Doctors Mess - Sheffield Hospitals Charity	37,000				
JHW Bereavement Suite - Sheffield Hospitals Charity	0	122,000			
Laboratory Equipment - SHC/Danson Foundation	85,000				
NGH & RHH Junior Doctors Mess - Doctors Mess Contribution	7,000				
Medical Equipment - Sheffield Hospitals Charity	20,000				
Decarbonisation Skills Grant	94,000				
<b>Subtotal Donations/Other Income</b>	<b>1,189,000</b>	<b>822,000</b>	<b>700,000</b>	<b>700,000</b>	<b>700,000</b>
<b>TOTAL FUNDING AVAILABLE</b>	<b>60,206,000</b>	<b>35,083,000</b>	<b>25,586,000</b>	<b>21,410,000</b>	<b>21,519,000</b>

**PROGRAMMED EXPENDITURE 2020/21 - 2024/25**

**Appendix B**

**MEDICAL EQUIPMENT MODERNISATION**

APPROVED SCHEME DETAILS	SITE	SCHEME STATUS	INITIAL APPROVED SUM	LATEST APPROVED SUM	CUMULATIVE SPEND TO 31/3/19	REMAINING PROGRAMMED EXPENDITURE					PROJECT LEAD	BUDGET LEAD	
						2020/21	2021/22	2022/23	2023/24	2024/25			TOTAL
Annual Upgrade Programme	NGH	Approved				1,633,000	273,000				1,906,000	MDMG	CK
Annual Upgrade Programme	RHH	Approved				1,098,000	81,000				1,179,000	MDMG	CK
Annual Upgrade Programme	CCDH	Approved				288,000	0				288,000	MDMG	CK
Annual Upgrade Programme	JHW	Approved				74,000	120,000				194,000	MDMG	CK
Annual Upgrade Programme	WPH	Approved				0	0				0	MDMG	CK
Annual Upgrade Programme	CHS	Approved				197,000	0				197,000	MDMG	CK
Annual Upgrade Programme	STH	Approved				857,000	817,000				1,674,000	MDMG	CK
Annual Upgrade Programme - Unallocated	STH	Planning Sum				546,000	2,845,000	3,200,000	3,200,000	3,200,000	12,991,000	MDMG	CK
Major Equipment Replacement Programme	STH	Planning Sum				0	4,711,000	3,000,000	3,000,000	3,000,000	13,711,000	MDMG	CK
Donated Medical Equipment	NGH	Approved				98,000	0				98,000	MDMG	CK
Donated Medical Equipment	RHH	Approved				7,000	0				7,000	MDMG	CK
Donated Medical Equipment	CCDH	Approved				0					0	MDMG	CK
Donated Medical Equipment	JHW	Approved				0					0	MDMG	CK
Donated Medical Equipment	WPH	Approved				0					0	MDMG	CK
Donated Medical Equipment	CHS	Approved				0					0	MDMG	CK
Clinical Skills Equipment	NGH	Planning Sum									0	MDMG	CK
Clinical Skills Equipment	RHH	Planning Sum									0	MDMG	CK
Clinical Skills Equipment	JHW	Planning Sum									0	MDMG	CK
Clinical Skills Equipment	CCDH	Planning Sum									0	MDMG	CK
Clinical Skills Equipment	WPH	Planning Sum									0	MDMG	CK
Clinical Skills Equipment	CHS	Planning Sum									0	MDMG	CK
Replacement Cath Labs	NGH	Completed	1,073,000	2,788,000	2,764,715	23,000					23,000	C Monk	CM
NGH Plain Film Room Equipment	NGH	Phase 1 Completed; Phase 2 FBC Approved	1,080,000	2,761,000	2,219,745	540,000					540,000	P Bailey	PBa
RHH Plain Film Room Equipment	RHH	Completed	540,000	1,345,000	1,075,848	270,000					270,000	P Bailey	PBa
Fluroscopy Replacement x2, NGH	NGH	FBC Approved	1,000,000	1,046,000	507,288	539,000					539,000	P Bailey	PBa
Symptomatic & Assessment Mammography Equip	RHH	Completed	664,000	1,200,000	589,315	611,000					611,000	P Bailey	PBa
Replacement 3D Mobile Fluoroscopy	RHH	OBC Approved	300,000	300,000	0	300,000					300,000	P Bailey	PBa
8th Linear Accelerator	WPH	Completed	2,094,000	2,094,000	7,239	2,087,000					2,087,000	S Tozer-Loft	DC
Expansion Gastroenterology Scope capacity	NGH	Completed	210,000	271,000	0	271,000					271,000	L Walton	LW
COVID 19 Equipment	STH	Approved	1,746,000	3,495,000	0	3,495,000					3,495,000	P Whiting	PW
Gamma Camera Replacement	WPH	Fees	5,000	5,000	0	5,000					5,000	W Tindale	WT
ENT CO2 Laser	RHH	Completed	162,000	162,000	0	162,000					162,000	C Wilkie	CW
7th MRI Scanner	RHH	Fees	5,000	5,000	0	5,000					5,000	P Bailey	PBa
Retinal Imaging System for Retinopathy of Prematurity	JHW	Approved	135,000	135,000	0	135,000					135,000	P Bailey	PBa
Liquid Chromatography Mass Spectrometry x2	NGH	OBC Approved	400,000	400,000	0	400,000					400,000	P Bailey	PBa
<b>MEDICAL EQUIPMENT MODERNISATION TOTAL</b>						<b>13,641,000</b>	<b>8,847,000</b>	<b>6,200,000</b>	<b>6,200,000</b>	<b>6,200,000</b>	<b>41,088,000</b>		

**INFORMATION TECHNOLOGY**

APPROVED SCHEME DETAILS	SITE	SCHEME STATUS	INITIAL APPROVED SUM	LATEST APPROVED SUM	CUMULATIVE SPEND TO 31/3/19	REMAINING PROGRAMMED EXPENDITURE					PROJECT LEAD	BUDGET LEAD	
						2020/21	2021/22	2022/23	2023/24	2024/25			TOTAL
General IT Systems/Telecoms Development	NGH	Approved				12,000	254,000				266,000	S Addy	MN
General IT Systems/Telecoms Development	RHH	Approved				16,000	0				16,000	S Addy	MN
General IT Systems/Telecoms Development	WPH	Approved				5,000	0				5,000	S Addy	MN
General IT Systems/Telecoms Development	JHW	Approved				0	0				0	S Addy	MN
General IT Systems/Telecoms Development	CHS	Approved				0	0				0	S Addy	MN
General IT Systems/Telecoms Development	STH	Approved				1,291,000	712,000				2,003,000	S Addy	MN
Informatics Strategic & Corporate - Unallocated	STH	Planning Sum				20,000	0	1,250,000	1,250,000	1,250,000	3,770,000	S Addy	MN
Informatics Infrastructure - Unallocated	STH	Planning Sum				8,000	0	487,000	500,000	500,000	1,495,000	S Addy	MN
Renal Information System	NGH	Completed	426,000	531,000	496,568	8,000	28,000				36,000	C Monk	CM
Ophthalmology Clinical Data Management System	RHH	Completed	7,000	406,000	405,528	0					0	C Wilkie	CW
Purchase to Pay Software	NGH	Approved	109,000	106,000	31,954	30,000	45,000				75,000	N Priestley	NP
PACS	STH	FBC Approved	242,000	2,862,000	2,147,764	484,000	231,000				715,000	S Addy	MN
Wired Network Core	STH	Approved	600,000	1,573,000	1,136,741	436,000					436,000	S Addy	MN
Inventory Management System	STH	Planning Sum	692,000	692,000	9,490	21,000	662,000				683,000	A Smith	NP
PSA Remote Test Results	STH	Completed	40,000	27,000	24,782	2,000					2,000	P Buckley	PB
EPR Implementation	STH	Approved	148,000	148,000	0	0	148,000				148,000	D Hughes	MN
Cardiac Critical Care EPR/Metavision	NGH	FBC Approved	469,000	469,000	0	110,000	359,000				469,000	C Monk	MN
Ophthalmology MERGE System	RHH	OBC Approved	535,000	535,000	0	535,000					535,000	C Wilkie	MN
<b>INFORMATION TECHNOLOGY TOTAL</b>						<b>2,978,000</b>	<b>2,439,000</b>	<b>1,737,000</b>	<b>1,750,000</b>	<b>1,750,000</b>	<b>10,654,000</b>		

**SERVICE DEVELOPMENT**

APPROVED SCHEME DETAILS	SITE	SCHEME STATUS	INITIAL APPROVED SUM	LATEST APPROVED SUM	CUMULATIVE SPEND TO 31/3/19	REMAINING PROGRAMMED EXPENDITURE					TOTAL	PROJECT LEAD	BUDGET LEAD
						2020/21	2021/22	2022/23	2023/24	2024/25			
New Business Planning Rounds/Service Development	STH	Planning Sum				0	1,984,000	3,550,000	3,550,000	3,550,000	12,634,000	CIT	CIT
A&E Decontamination Unit, NGH	NGH	Approved/On Hold	188,000	380,000	330,606	0	50,000				50,000	C Powell-Wiffen	CN
Bowel Cancer Screening Accommodation	RHH	Planning Sum	150,000	200,000	167,392	0	33,000				33,000	C Powell-Wiffen	CN
WPH Redevelopment/Expansion	WPH	Fees	30,000	146,000	146,069						0	I Scott	CN
WPH- JHW Link Bridge	WPH	Completed	60,000	3,593,000	3,516,557	76,000					76,000	I Scott	CN
Pharmacy Aseptic Unit, WPH	WPH	FBC Approved	30,000	4,069,000	2,566,591	115,000	1,387,000				1,502,000	D Child	CN
Hyper Acute Stroke Unit	RHH	FBC Approved; Phase 1 completed	5,000	5,847,000	3,097,217	2,749,000					2,749,000	C Wilkie	CN
Clinical Immunology & Allergy Unit Expansion	NGH	FBC Approved	5,000	2,118,000	180,783	1,831,000	106,000				1,937,000	D Campbell	CN
Firth 7/CCU	NGH	Fees/Planning Sum	5,000	300,000	39,184	0	261,000				261,000	C Monk	CN
MSK Integrated Hub	RHH	Completed	3,783,000	4,138,000	3,453,039	685,000					685,000	V Leckie	CN
5 Beech Hill Road Refurbishment	RHH	Completed	5,000	1,761,000	1,091,396	669,000					669,000	S Hindmarch	CN
16 Claremont Neurosciences Offices	RHH	Fees	5,000	5,000	-740	6,000					6,000	C Wilkie	CN
Expansion Clocktower Office Accommodation	NGH	Completed	8,000	1,054,000	1,047,300	7,000					7,000	S Hindmarch	CN
NGH Radiology D Floor Refurbishment	NGH	FBC Approved	5,000	1,295,000	831,591	117,000	346,000				463,000	P Bailey	CN
HIV Integration	RHH	Completed	3,000	182,000	82,877	99,000					99,000	D Campbell	CN
NGH Washer Disinfectors	NGH	Fees	5,000	5,000	1,879	3,000					3,000	M Harper	CN
Endocrine Investigation Unit	RHH	FBC Approved	5,000	898,000	20,113	180,000	698,000				878,000	L Walton	CN
Community Dental Services - Wheata	CHS	FBC Approved	10,000	2,633,000	42,518	1,384,000	1,206,000				2,590,000	C Wilkie	CN
Community Dental Services - Manor	CHS	FBC Approved	662,000	662,000	0	662,000					662,000	C Wilkie	CN
MDT Rooms x3	STH	FBC Approved	318,000	420,000	354,006	22,000	44,000				66,000	P Buckley	CN
Replacement of UoS 1.5T MRI	RHH	Fees	5,000	5,000	0	5,000					5,000	S Hindmarch	CN
Doctors Mess Redevelopment	NGH	Completed	1,000	115,000	30,011	85,000					85,000	J Hill	CN
Chesterfield Renal Satellite Unit	CHS	Withdrawn	1,000,000	0	0	0	0				0	C Monk	CN
Purchase of Longley Lane	NGH	FBC Approved	750,000	1,000,000	4,692	996,000					996,000	S Hindmarch	CN
JHW Breavement Suite	JHW	Approved	3,000	229,000	3,711	60,000	165,000				225,000	P Bailey	CN
Medical Examiners Office/Breavement Suite	NGH	Completed	3,000	98,000	1,757	96,000					96,000	A Gibson	CN
Mortuary Facilities	NGH	Completed	155,000	155,000	2,342	153,000					153,000	P Bailey	CN
NGH Hip Fracture Ward (Huntsman 5)	NGH	OBC Approved	3,000	2,176,000	29,150	50,000	2,097,000				2,147,000	S Gregory	CN
Gastroenterology Facilities	RHH	Fees	5,000	10,000	5,069	5,000					5,000	S Hindmarch	CN
NGH Radiology Outpatient Centre	NGH	Fees	2,000	2,000	0	2,000					2,000	P Bailey	CN
RHH Bed Storage Area	RHH	Completed	200,000	190,000	9,875	180,000					180,000	K Jessop	CN
Expansion Coleridge House Accommodation	NGH	Completed	78,000	55,000	4,817	50,000					50,000	J Wright	CN
RHH C Floor Breast Clinic Refurbishment	RHH	Approved	5,000	801,000	0	30,000	771,000				801,000	P Bailey	CN
Chesterman 3/4 - Renal Transplant Facilities	NGH	Completed	38,000	38,000	0	38,000					38,000	C Monk	CN
Diabetes & Endocrinology Security	RHH	Approved	11,000	11,000	0	11,000					11,000	L Walton	CN
ED Reconfiguration	NGH	Withdrawn	5,000	0	0	0					0	C Powell-Wiffen	CN
Infectious Diseases High Consequence Facility	RHH	Fees	2,000	2,000	0	2,000					2,000	D Campbell	CN
Blood Disorders Facilities	RHH	Fees	2,000	2,000	0	2,000					2,000	D Campbell	CN
Critical Care K Floor Pharmacy	RHH	Completed	99,000	99,000	0	99,000					99,000	C Wilkie	CN

NGH Pharmacy Accommodation Expansion	NGH	Approved	458,000	458,000	0	20,000	438,000				458,000	D Child	CN
Relocation SAC to TAU/Huntsman 2	NGH	Fees	5,000	5,000	0	5,000					5,000	C Powell-Wiffen	CN
Ultraviolet C Decontamination Equipment	STH	Planning Sum	110,000	110,000	0	110,000					110,000	M Harper	MH
<b>SERVICE DEVELOPMENT TOTAL</b>						<b>10,604,000</b>	<b>9,586,000</b>	<b>3,550,000</b>	<b>3,550,000</b>	<b>3,550,000</b>	<b>30,840,000</b>		

**INFRASTRUCTURE**

APPROVED SCHEME DETAILS	SITE	SCHEME STATUS	INITIAL APPROVED SUM	LATEST APPROVED SUM	CUMULATIVE SPEND TO 31/3/19	REMAINING PROGRAMMED EXPENDITURE					TOTAL	PROJECT LEAD	BUDGET LEAD
						2020/21	2021/22	2022/23	2023/24	2024/25			
Facilities & Security Infrastructure	NGH	Approved				257,000	48,000				305,000	A Jones	AJ
Facilities & Security Infrastructure	RHH	Approved				33,000	15,000				48,000	A Jones	AJ
Facilities & Security Infrastructure	JHW	Approved				0	0				0	A Jones	AJ
Facilities & Security Infrastructure	CCDH	Approved				0	0				0	A Jones	AJ
Facilities & Security Infrastructure	WPH	Approved				12,000	0				12,000	A Jones	AJ
Facilities & Security Infrastructure	STH	Approved				24,000	0				24,000	A Jones	AJ
Facilities & Security Infrastructure - Unallocated	STH	Planning Sum				0	809,000	400,000	400,000	400,000	2,009,000	A Jones	AJ
Estates Infrastructure	STH	Planning Sum				20,000	8,100,000	3,400,000	3,400,000	3,400,000	18,320,000	S Hindmarch	SH
Ward Refurbishment Programme	STH	Planning Sum				0	2,247,000	2,750,000	2,750,000	2,750,000	10,497,000	K Jessop	SH
Non-Clinical Public Environments Programme	STH	Planning Sum				0	740,000	400,000	400,000	400,000	1,940,000	K Jessop	SH
Theatre Refurbishment/Expansion Programme	STH	Planning Sum				0	4,366,000	2,000,000	2,000,000	2,000,000	10,366,000	S Hindmarch	SH
RHH A Floor Theatres	RHH	FBC Approved	36,000	18,837,000	11,806,452	5,128,000	1,903,000				7,031,000	S Hindmarch	CN
Hadfield Lifecycle Assets	NGH	Approved				865,000	936,000	692,000	648,000	690,000	3,831,000	S Hindmarch	CN
RHH Main Lifts	RHH	Approved	6,500,000	5,448,000	2,923,068	1,757,000	768,000	0			2,525,000	S Hindmarch	CN
Service Block Redevelopment	RHH	Fees/Approved	1,050,000	2,224,000	1,268,527	106,000	850,000				956,000	S Hindmarch	CN
NGH Vickers 16 & 17 Car Parking	NGH	Withdrawn	297,000	126,000	126,286	0	0				0	S Hindmarch	CN
RHH LTHW	RHH	Approved	15,000	3,575,000	2,181,300	323,000	1,070,000				1,393,000	S Hindmarch	CN
Firth Wing Theatres	NGH	FBC Approved	5,000	5,427,000	2,821,175	2,606,000					2,606,000	S Hindmarch	CN
NGH LV Generators	NGH	Approved	32,000	1,366,000	25,697	1,340,000					1,340,000	S Hindmarch	CN
CCTV Upgrade	STH	OBC Approved	10,000	765,000	-300	5,000	760,000				765,000	A Jones	AJ
Jessops Wing Ward Refurbishment	JHW	Fees	5,000	45,000	45,639						0	S Hindmarch	CN
Chesterman Theatres	NGH	Fees	8,000	13,000	13,165						0	S Hindmarch	CN
Barnsley Renal Satellite Unit	CHS	Completed	5,000	79,000	351	78,000					78,000	S Hindmarch	CN
NGH CHP	NGH	Fees	5,000	15,000	5,347	9,000					9,000	S Hindmarch	CN
JHW Theatre Refurbishment	JHW	Fees	10,000	10,000	0	10,000					10,000	S Hindmarch	CN
RHH Ward H1 Refurbishment	RHH	Planning Sum	1,520,000	1,520,000	0	20,000	1,500,000				1,520,000	S Hindmarch	CN
WPH External Cladding	WPH	Fees	5,000	5,000	0	5,000					5,000	S Hindmarch	CN
Vicker 4 Ward Refurbishment	NGH	Completed	720,000	720,000	0	720,000					720,000	B Brewis	CN
RHH B Road	RHH	Fees	10,000	10,000	0	10,000					10,000	S Hindmarch	CN
CCDH Covid Restart	CCDH	Fees	15,000	1,901,000	0	1,001,000	900,000				1,901,000	C Wilkie	CN
Critical Risk Infrastructure	STH	Planning Sum	12,778,000	0	0	0					0	S Hindmarch	CN
RHH T Floor Chillers	RHH	Approved	1,300,000	1,120,000	0	1,020,000	100,000				1,120,000	S Hindmarch	CN
Critical Care Chiller Unit Replacement	NGH	Approved	300,000	420,000	0	420,000					420,000	S Hindmarch	CN
Brearley Wing LV Supply	NGH	Approved	400,000	270,000	0	270,000					270,000	S Hindmarch	CN
CPU LV Generator	NGH	Approved	300,000	410,000	0	410,000					410,000	S Hindmarch	CN
Chesterman Cooling Systems	NGH	Approved	500,000	95,000	0	25,000	70,000				95,000	S Hindmarch	CN

Labs Alternate Power Supply	NGH	Approved	250,000	300,000	0	300,000					300,000	S Hindmarch	CN
Vickers Verandah Refurbishment	NGH	Approved	600,000	725,000	0	300,000	425,000				725,000	S Hindmarch	CN
Clocktower LV Supply	NGH	Approved	250,000	320,000	0	320,000					320,000	S Hindmarch	CN
Vicker 11/12 Roof	NGH	Approved	200,000	400,000	0	250,000	150,000				400,000	S Hindmarch	CN
Ultrasound Facilities (former Pain Clinic)	NGH	Completed	20,000	20,000	0	20,000					20,000	P Bailey	CN
Central Clinic Lift/Pre-Op Refurbishment	CHS	Approved	183,000	875,000	0	850,000	25,000				875,000	S Hindmarch	CN
Chaplaincy/Ambulance Building Car Parking	NGH	Approved	143,000	143,000	58,122	85,000					85,000	S Hindmarch	CN
Decarbonisation Initiatives	STH	Approved	94,000	94,000	0	94,000					94,000	S Hindmarch	CN
Estates Vehicle replacement	NGH	Approved	24,000	24,000	0	24,000					24,000	S Hindmarch	CN
<b>INFRASTRUCTURE TOTAL</b>						<b>18,717,000</b>	<b>25,782,000</b>	<b>9,642,000</b>	<b>9,598,000</b>	<b>9,640,000</b>	<b>73,379,000</b>		

**LEASED ASSETS**

APPROVED SCHEME DETAILS	SITE	SCHEME STATUS	INITIAL APPROVED SUM	LATEST APPROVED SUM	CUMULATIVE SPEND TO 31/3/19	REMAINING PROGRAMMED EXPENDITURE					PROJECT LEAD	BUDGET LEAD	
						2020/21	2021/22	2022/23	2023/24	2024/25			TOTAL
High Resolution Mass Spectrometer (Toxicology)	NGH	Approved	449,000	449,000	0	449,000					449,000	P Bailey	PBa
<b>LEASED ASSET TOTAL</b>						<b>449,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>449,000</b>		

**OTHER**

APPROVED SCHEME DETAILS	SITE	SCHEME STATUS	INITIAL APPROVED SUM	LATEST APPROVED SUM	CUMULATIVE SPEND TO 31/3/19	REMAINING PROGRAMMED EXPENDITURE					PROJECT LEAD	BUDGET LEAD	
						2020/21	2021/22	2022/23	2023/24	2024/25			TOTAL
Planned rev-cap Transfers/Redefinition of Capital	STH	Planning Sum				63,000	300,000	300,000	300,000	300,000	1,263,000	N Priestley	NP
Funding for Unfunded Schemes	STH	Planning Sum									0	N Priestley	NP
Directly Donated Equipment	RHH	Planning Sum									0	N Priestley	NP
<b>TOTAL PROGRAMMED EXPENDITURE</b>						<b>46,452,000</b>	<b>46,954,000</b>	<b>21,429,000</b>	<b>21,398,000</b>	<b>21,440,000</b>	<b>157,673,000</b>		



## 2020/21 - 2024/25 CAPITAL PROGRAMME - RISKS AND CONTINGENCIES SUMMARY

<b>Known Risks:</b>	20/21 Unallocated Budget	2020/21 £	2021/22 £	2022/23 £	2023/24 £	2024/25 £	
<b>Ring fenced Envelopes:</b>							
Medical Equipment	546,000						Envelope commitment not yet complete. Further options to be reviewed
Major Equipment	0						
Informatics Strategic & Corporate	20,000						JAC System Upgrade £26k, although likely slippage to 21/22
Informatics Infrastructure	8,000						Planned cases, awaiting development/approval: Room Booking System re COVID - costs/funding route TBC
Service Development	0						
Facilities & Security Infrastructure	0						
Estates Infrastructure	20,000						No plans. Slippage risk included below
Ward Refurbishment Programme	0						
Non Clinical Public Environments	0						
Theatre Refurbishment Programme	0						
<b>Risks Expected to Emerge in Short-Term (not yet fully quantified/confirmed):</b>							
<b>Cost Increases to approved schemes:-</b>							
<b>a) Schemes previously advised completed:</b>							
- Unfunded schemes							
- Equipment in consumables deals		400,000					Value TBC and nature of arrangement, but expectation will be defined as Finance lease under IAS 17
<b>b) Ongoing Schemes/Schemes in development:</b>							
- RHH plain film room		?					Potential cost pressure being quantified
- Chemocare		?					Re Doncaster link
- WPH/JHW Link Bridge		100,000					Minimum Contractor claim/overspend
- MSK Integrated Hub		21,000					Potential cost pressure being quantified
- Community Dentistry Wheata			63,000				Tender return pressure - includes COVID ventilation
- Huntsman 5			400,000				Expected tender pressure from programmed sum
<b>Cost Reductions to approved schemes:-</b>							
- Inventory Management System		?					Potential funding via Vaccine Hub funding £130k (paper to CIT 23/11/20)
- Central Clinic Refurbishment		?					Contribution from GPs towards lift under discussion
<b>Subtotal - Expected Net Commitments/(Savings)</b>		<b>521,000</b>	<b>463,000</b>	<b>0</b>	<b>0</b>	<b>0</b>	

<b>Slippage Risks:</b>						
- Renal Dialysis Phase 4	?	?				Phase 4 £355k. Delivery risks re training capacity/COVID impact
- Cardiac Stack System	123,000	-123,000				Procurement in progress/order not yet placed
- Prosthodontics CAD/CAM System	58,000	-58,000				Procurement in progress/order not yet placed
- Urodynamic Analyser	18,000	-18,000				Procurement in progress/order not yet placed
- Ultrasound Scanner x4	68,000	-68,000				Procurement in progress/order not yet placed
- Belmont Rapid Infusion	23,000	-23,000				Procurement in progress/order not yet placed
- Restorative Dentistry Microscopes (CCDH)	121,000	-121,000				Procurement in progress/order not yet placed
- MDMG Unallocated	546,000	-546,000				Unallocated envelope
- Replacement Cath Labs	23,000	-23,000				Slippage not yet utilised
- NGH Plain Film Rooms	?	?				Potential impact of COVID on scheme delivery - currently expect to complete 3 machines. Risk of one machine £270k due for Feb delivery
- NGH Fluoroscopy	?	?				Potential impact of COVID on scheme delivery - plan in place for Feb 21 delivery. Risk £419k re equip
- Symptomatic & Assessment Mammography	25,000	-25,000				Potential saving being quantified
- Replacement 3D Mobile Fluoroscopy	300,000	-300,000				Procurement in early stages
- Mass Spectrometry x2	400,000	-400,000				Procurement in early stages
- Endoscopy Recovery Equipment - Air Filtration Units	47,000	-47,000				No longer to be progressed - redeployment within Endoscopy still awaited
- Tom-Tech Echo Reporting System	80,000	-80,000				National funding - case yet to be progressed
- Purchase to Pay	10,000	-10,000				Slippage risk on Cherwell implementation due to IT capacity
- PACS	200,000	-200,000				Project restart delayed/slippage from additional works identified by supplier
- Wired Network Core	?	?				Potential slippage in professional services from supplier
- Cardiac Critical Care EPR/Metavision	?	?				Delivery of hardware anticipated before year end £110k, but slippage risk
- Ophthalmology Merge System	535,000	-535,000				Supplier confirmation not anticipated until mid Feb
- Flexpod Infrastructure	58,000	-58,000				Potential savings identified in tender evaluation
- Informatics Strategic & Corporate	28,000	-28,000				Unallocated envelope
- Ultraviolet C Decontamination Equipment	110,000	-110,000				Change of supplier - unclear if rent to buy option available from new owner
- HASU	949,000	-949,000				Estimate, based on revised funding projection £315k and £634k potential savings
- Purchase Longley Lane	64,000	-64,000				Savings being quantified. Budget £1m cf case to Board at £936k
- Automatic Number Plate Recognition	24,000	-24,000				Plans not developed
- Security Review Access NGH	23,000	-23,000				Plans not developed
- Mattress Washing Equipment x2	85,000	-85,000				Procurement in early stages
- Estates Infrastructure	20,000	-20,000				Unallocated envelope
- RHH A Floor Theatres	?	?				Monitoring of major scheme to continue
- Critical Infrastructure Risk schemes	?	?				Unclear if access for shut down processes will be granted during COVID resurgence
- Further COVID restrictions on construction, supply chain and planning capacity	?	?				Generic risk across all areas
	3,938,000	-3,938,000	0	0	0	
<b>Advancement Opportunities:</b>						
- Community Wi-Fi	-115,000	115,000				Phase 1 of Trust wide AP tender
- NGH Modular Wards	?	?				Cost pressure being investigated re Fire Testing ground floor - up to £200k
- Gastroenterology Facilities	?	?				Add'l fee request £45k
- Hadfield re-equipping	?	?				Potential Bath Hoists x 3 £41k and Dishwashers £24k - still under consideration
	-115,000	115,000	0	0	0	

<b>Possible Contingencies:</b>		2020/21	2021/22	2022/23	2023/24	2024/25	
		£	£	£	£	£	
<b>Additional Income:</b>							
Charitable/Donated Funds		?	?	?	?	?	
National IT PDC Funding		?	?	?	?	?	National Technology Funding, Potential share national £1.5bn re A&E
National PDC Funding		?	?	?	?	?	Potential for £110k Colon Capsule Endoscopy System, TBC Mechanical Thrombotomy Bi-plane, LIMS bid £929k Hub re upgrade of ICE to ICE Enterprise, PACS/RIS Shared Image Platform over SY&B
COVID Funding		?					STH underwrite of £846k of bids assumed unsuccessful. Possible CCDH Restart contribution £782k
<b>Other:</b>							
Increase in Internally Generated resources/Re-invest I&E surplus		?	?	?	?	?	Low likelihood under 20/21 financial regime
Use of STH Cash balances					?	?	Expected to be required from 2023/24 onwards, given low PSF Funding availability
Borrowing Facility		?	?	?	?	?	Schemes to be identified.
Lease rather than purchase future Major Equipment		?	?	?	?	?	Revenue consequences
Potential reduction to ring fenced capital budgets		?	?	?	?	?	
Removal prioritised schemes		?	?	?	?	?	
VAT recovery		?	?	?	?	?	Low likelihood given current HMRC considerations
		0	0	0	0	0	